Literature DB >> 28345461

Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma.

Ze-Wu Meng1,2, Min-Chao Liu1,2, Hai-Jie Hong1,2, Qiang Du1,2, Yan-Ling Chen1,2.   

Abstract

The incidence rate of intrahepatic cholangiocarcinoma is rising, and treatment options are limited. Therefore, new biological markers of intrahepatic cholangiocarcinoma are needed. Immunohistochemistry and enzyme-linked immunosorbent assay were applied to analyze the expressions of CD97, CD55, and soluble CD97 in 71 patients with intrahepatic cholangiocarcinoma and 10 patients with hepatolithiasis. CD97 and CD55 were not expressed in hepatolithiatic tissues, but positive expression was observed in 76.1% (54/71) and 70.4% (50/71) of intrahepatic cholangiocarcinoma patients. The univariate analyses indicated that the positive expressions of CD97 and CD55 were related to short intrahepatic cholangiocarcinoma survival of patients (both p = 0.001). Furthermore, CD97 and CD55 expressions and biliary soluble CD97 levels were significantly associated with histological grade (p = 0.004, 0.002, and 0.012, respectively), lymph node metastases (p = 0.020, 0.038, and 0.001, respectively), and venous invasion (p = 0.003, 0.002, and 0.001, respectively). The multivariate analyses indicated that lymph node metastases (hazard ratio: 2.407, p = 0.003), positive CD55 expression (hazard ratio: 4.096, p = 0.003), and biliary soluble CD97 levels (hazard ratio: 2.434, p = 0.002) were independent risk factors for the intrahepatic cholangiocarcinoma survival. The receiver operating characteristic (ROC) curve analysis indicated that when the cutoff values of biliary soluble CD97 were 1.15 U/mL, the diagnostic value for predicting lymph node metastasis had a sensitivity of 87.5% and a specificity of 51.3%. For intrahepatic cholangiocarcinoma patient death within 60 months at a cutoff value of 0.940 U/mL, the diagnostic value sensitivity was 89.3% and the specificity was 93.3%. Biliary soluble CD97 may be a new biological marker for early diagnosis, prediction of lymph node metastasis and poor prognosis, and discovery of a therapeutic target.

Entities:  

Keywords:  CD55; CD97; intrahepatic cholangiocarcinoma; prognosis; soluble CD97

Mesh:

Substances:

Year:  2017        PMID: 28345461     DOI: 10.1177/1010428317694319

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  10 in total

Review 1.  The Emerging Role of Adhesion GPCRs in Cancer.

Authors:  Abanoub A Gad; Nariman Balenga
Journal:  ACS Pharmacol Transl Sci       Date:  2020-01-13

Review 2.  To Detach, Migrate, Adhere, and Metastasize: CD97/ADGRE5 in Cancer.

Authors:  Gabriela Aust; Leyu Zheng; Marianne Quaas
Journal:  Cells       Date:  2022-05-04       Impact factor: 7.666

Review 3.  Beyond the Role of CD55 as a Complement Component.

Authors:  So Hee Dho; Jae Cheong Lim; Lark Kyun Kim
Journal:  Immune Netw       Date:  2018-02-20       Impact factor: 5.851

4.  Cell-to-cell expression dispersion of B-cell surface proteins is linked to genetic variants in humans.

Authors:  Gérard Triqueneaux; Claire Burny; Orsolya Symmons; Stéphane Janczarski; Henri Gruffat; Gaël Yvert
Journal:  Commun Biol       Date:  2020-07-03

Review 5.  The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy.

Authors:  Anne Geller; Jun Yan
Journal:  Front Immunol       Date:  2019-05-21       Impact factor: 7.561

Review 6.  Complement in Metastasis: A Comp in the Camp.

Authors:  Daniel Ajona; Sergio Ortiz-Espinosa; Ruben Pio; Fernando Lecanda
Journal:  Front Immunol       Date:  2019-04-03       Impact factor: 7.561

Review 7.  Complement and Cancer-A Dysfunctional Relationship?

Authors:  Joshua M Thurman; Jennifer Laskowski; Raphael A Nemenoff
Journal:  Antibodies (Basel)       Date:  2020-11-05

Review 8.  "Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma.

Authors:  Astha Malik; Unmesha Thanekar; Surya Amarachintha; Reena Mourya; Shreya Nalluri; Alexander Bondoc; Pranavkumar Shivakumar
Journal:  Front Oncol       Date:  2021-02-24       Impact factor: 5.738

Review 9.  Prognostic and Predictive Molecular Markers in Cholangiocarcinoma.

Authors:  Sandra Pavicevic; Sophie Reichelt; Deniz Uluk; Isabella Lurje; Cornelius Engelmann; Dominik P Modest; Uwe Pelzer; Felix Krenzien; Nathanael Raschzok; Christian Benzing; Igor M Sauer; Sebastian Stintzing; Frank Tacke; Wenzel Schöning; Moritz Schmelzle; Johann Pratschke; Georg Lurje
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

10.  Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.

Authors:  Zhihui Weng; Jiacheng Lin; Jiaozi He; Lin Gao; Sien Lin; Lai Ling Tsang; Hang Zhang; Xiaoyan He; Guang Wang; Xuesong Yang; Hu Zhou; Hui Zhao; Gang Li; Lin Zou; Xiaohua Jiang
Journal:  Neuro Oncol       Date:  2022-06-01       Impact factor: 13.029

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.